Drug Equality Alliance

Last updated

The Drug Equality Alliance is a non-profit organisation based in the United Kingdom whose mission statement is:

Contents

[...] It is made to transform the "War on Some People who use Some Drugs" from its subjective historical and cultural roots into a rational and objective legal regulatory framework that secures equal rights and equal protection to all those who are concerned with dangerous or otherwise harmful drugs. Our mission is to use domestic and international legal jurisdictions to interrogate the law and its application to those who produce, commerce, possess and consume such drugs. [1]

The Drug Equality Alliance believes that the UK Government is administering the Misuse of Drugs Act 1971 in an arbitrary and discriminatory manner. This is contrary to the purpose of the Act, contrary to the original wishes of Parliament, conflicts with the European Convention on Human Rights, and is therefore illegal. It argues that the penalties associated with the possession, production and supply of various controlled substances are not proportional to the relative harms which these substances cause to individuals and society, especially since two of the most dangerous drugs, alcohol and tobacco, are presently excluded from the Act. The Drug Equality Alliance is currently assisting and supporting several legal challenges in relation to this alleged maladministration. [2] [3] [4] [5] [6] [7]

As evidence that the Misuse of Drugs Act 1971 is being administered arbitrarily, the Drug Equality Alliance cites the following admission made by the Government in "The Government Reply to the Fifth Report from the House of Commons Science and Technology Committee Session 2005-6 HC 1031: Drug classification: making a hash of it?" (Cm 6941):

...the Government acknowledges that alcohol and tobacco account for more health problems and deaths than illicit drugs.... The distinction between legal and illegal substances is not unequivocally based on pharmacology, economic or risk benefit analysis. It is also based in large part on historical and cultural precedents. [8]

In March 2010, in response to a Freedom of Information request process submitted by Casey William Hardison, acting with the Drug Equality Alliance, the Information Commissioner's Office ordered the Home Office to disclose a suppressed draft consultation paper with suggestions for a review of the drug classification system. [9] [10] [11] [12] This decision was subject to a last minute appeal by the Home Office, but the appeal was withdrawn on 9 July 2010 and the consultation paper was released on 12 July 2010. [13]

The web address and website of the organisation originated in 2008. The respective web address was last recorded as directing to the organisation's official website up until 6 July 2022. Since 17 October 2022, it has been recorded as either inaccessible or redirecting to other unrelated content to the organisation (such as a gambling website). [14]

See also

Related Research Articles

<span class="mw-page-title-main">Controlled Substances Act</span> United States drug-regulating law

The Controlled Substances Act (CSA) is the statute establishing federal U.S. drug policy under which the manufacture, importation, possession, use, and distribution of certain substances is regulated. It was passed by the 91st United States Congress as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and signed into law by President Richard Nixon. The Act also served as the national implementing legislation for the Single Convention on Narcotic Drugs.

<span class="mw-page-title-main">Drug prohibition</span> History, effects and enforcement of the prohibition of drugs

The prohibition of drugs through sumptuary legislation or religious law is a common means of attempting to prevent the recreational use of certain intoxicating substances.

<span class="mw-page-title-main">Misuse of Drugs Act 1971</span> United Kingdom legislation

The Misuse of Drugs Act 1971 is an act of the Parliament of the United Kingdom. It represents action in line with treaty commitments under the Single Convention on Narcotic Drugs, the Convention on Psychotropic Substances, and the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.

Commonly-cited arguments for and against the prohibition of drugs include the following:

The Multidisciplinary Association for Psychedelic Studies (MAPS) is an American nonprofit organization working to raise awareness and understanding of psychedelic substances. MAPS was founded in 1986 by Rick Doblin and is now based in San Jose, California.

Jon B. Gettman is a marijuana rights activist, a leader of the Coalition for Rescheduling Cannabis, and a former head of the National Organization for the Reform of Marijuana Laws. He has a PhD in public policy and regional economic development from George Mason University and is a longtime contributor to High Times magazine. Gettman filed a petition in 1995 to remove cannabis from Schedule I of the Controlled Substances Act that was eventually denied. A second petition was filed in 2002, with the Coalition for Rescheduling Cannabis, that remains under review by the Department of Health and Human Services. Gettman frequently publishes on the marijuana industry and is an associate professor of Criminology and Criminal Justice at Shenandoah University in Virginia.

<span class="mw-page-title-main">Removal of cannabis from Schedule I of the Controlled Substances Act</span> Proposed changes to the legal status of cannabis in U.S. federal law

In the United States, the removal of cannabis from Schedule I of the Controlled Substances Act is a proposed legal and administrative change in cannabis-related law at the federal level. It has been proposed repeatedly since 1972. The category is the most tightly restricted category reserved for drugs that have "no currently accepted medical use."

The Alliance for Cannabis Therapeutics (ACT) is an organization supporting medical marijuana that was founded in 1981 by Robert C. Randall and Alice O'Leary. Randall was the first person known to have successfully used medical necessity as a defense against a charge of marijuana possession in violation of the Controlled Substances Act.

Cannabis classification in the United Kingdom refers to the class of drugs, as determined by the Misuse of Drugs Act 1971, that cannabis is placed in. Between 1928 and 2004 and since 2009, it has been classified as a class B drug. From 2004 to 2009, it was a class C drug. At present, it is a class B, with very limited exceptions.

<span class="mw-page-title-main">Misuse of Drugs Act 1975</span> Act of Parliament in New Zealand

The Misuse of Drugs Act 1975 is a New Zealand drug control law that classifies drugs into three classes, or schedules, purportedly based on their projected risk of serious harm. However, in reality, classification of drugs outside of passing laws, where the restriction has no legal power, is performed by the governor-general in conjunction with the Minister of Health, neither of whom is actually bound by law to obey this restriction.

The Advisory Council on the Misuse of Drugs (ACMD) is a British statutory advisory non-departmental public body, which was established under the Misuse of Drugs Act 1971.

Salvia divinorum, a psychoactive plant, is legal in most countries. Exceptions, countries where there is some form of control, include Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Italy, Japan, South Korea, Norway, Poland, United Kingdom, Ukraine, Spain, Sweden, Armenia and 33 states and territories of the United States.

Drug classification: making a hash of it? is a 2006 report written by the UK Science and Technology Select Committee and submitted to the British House of Commons. The report suggested that the current system of recreational drug classification in the UK was arbitrary and unscientific, suggesting a more scientific measure of harm be used for classifying drugs. The report also strongly criticised the decision to place fresh psychedelic mushrooms in Class A, the same category as cocaine and heroin.

<span class="mw-page-title-main">Cannabis in Oregon</span> Use of cannabis in Oregon

Cannabis in Oregon is legal for both medical and recreational use. In recent decades, the U.S. state of Oregon has had a number of legislative, legal, and cultural events surrounding use of cannabis. Oregon was the first state to decriminalize the possession of small amounts of cannabis, and among the first to authorize its use for medical purposes. An attempt to recriminalize possession of small amounts of cannabis was turned down by Oregon voters in 1997.

<span class="mw-page-title-main">Synthetic cannabinoids</span> Designer drugs

Synthetic cannabinoids are a class of designer drug molecules that bind to the same receptors to which cannabinoids in cannabis plants attach. These novel psychoactive substances should not be confused with synthetic phytocannabinoids or synthetic endocannabinoids from which they are in many aspects distinct.

<span class="mw-page-title-main">Medical cannabis in the United States</span> Use of cannabis for medical purposes in the United States

In the United States, the use of cannabis for medical purposes is legal in 38 states, four out of five permanently inhabited U.S. territories, and the District of Columbia, as of March 2023. Ten other states have more restrictive laws limiting THC content, for the purpose of allowing access to products that are rich in cannabidiol (CBD), a non-psychoactive component of cannabis. There is significant variation in medical cannabis laws from state to state, including how it is produced and distributed, how it can be consumed, and what medical conditions it can be used for.

The production, distribution, and sale of methamphetamine is restricted or illegal in many jurisdictions.

A temporary class drug is a relatively new status for controlled drugs, which has been adopted in some jurisdictions, notably New Zealand and the United Kingdom, to attempt to bring newly synthesised designer drugs under legal control. The controlled drug legislation in these jurisdictions requires drug scheduling decisions to follow an evidence-based process, where the harms of the drug are assessed and reviewed so that an appropriate legal status can be assigned. Since many designer drugs sold in recent years have had little or no published research that could help inform such a decision, they have been widely sold as "legal highs", often for months, before sufficient evidence accumulates to justify placing them on the controlled drug schedules.

<span class="mw-page-title-main">Glossary of cannabis terms</span>

Terms related to cannabis include:

References

  1. ↑ "Drug Equality Alliance (DEA) - Mission Statement". Drugequality.org. Archived from the original on 2011-12-20. Retrieved 2012-01-04.
  2. ↑ "Drug Equality Alliance (DEA) - Cases". Drugequality.org. Archived from the original on 2022-03-31. Retrieved 2012-01-04.
  3. ↑ "Peter Tatchell: The government is about to face a challenge to its drugs policy | Comment is free | guardian.co.uk". The Guardian. 2011-05-05. Retrieved 2012-01-04.
  4. ↑ "Transform Drug Policy Foundation Blog: Government challenged on drugs law". Transform-drugs.blogspot.com. 2008-10-14. Retrieved 2012-01-04.
  5. ↑ "Teacher in court over drugs | Manchester Evening News - menmedia.co.uk". Manchester Evening News. 2009-03-25. Retrieved 2012-01-04.
  6. ↑ "Cannabis campaigner charged with possession (From Western Telegraph)". Westerntelegraph.co.uk. 2010-01-24. Retrieved 2012-01-04.
  7. ↑ Published on Monday 18 May 2009 10:24 (2009-05-18). "Cannabis test case in court - News". Wigan Today. Archived from the original on 2009-05-20. Retrieved 2012-01-04.{{cite web}}: CS1 maint: numeric names: authors list (link)
  8. ↑ "Drug classification: making a hash of it? CM 6941" (PDF). Retrieved 2012-01-04.
  9. ↑ "Drug Equality Alliance (DEA) - News". Drugequality.org. Archived from the original on 2011-11-19. Retrieved 2012-01-04.
  10. ↑ http://www.drugequality.org/files/FS50198230.pdf Archived 2010-04-15 at the Wayback Machine [ bare URL PDF ]
  11. ↑ UKCIA in News and comment (2010-03-14). "Government forced to publish consultation paper on the future of drugs classification 2006. | The UKCIA News Blog". Ukcia.org. Archived from the original on 2012-01-08. Retrieved 2012-01-04.
  12. ↑ UKCIA in News and comment (2010-03-15). "Freedom of Information ruling on drug classification proposals | The UKCIA News Blog". Ukcia.org. Archived from the original on 2012-01-08. Retrieved 2012-01-04.
  13. ↑ "Mark Easton's UK: Tension at heart of drug classification". BBC. 2010-07-12. Retrieved 2012-01-04.
  14. ↑ "Website archive calendar for drugequality.org". Wayback Machine. Retrieved 23 June 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.